Penumbra (NYSE:PEN) will be releasing its earnings data after the market closes on Monday, August 3rd. Analysts expect Penumbra to post earnings of ($0.48) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Penumbra (NYSE:PEN) last posted its earnings results on Thursday, May 7th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.06). Penumbra had a net margin of 7.04% and a return on equity of 5.72%. The firm had revenue of $137.33 million during the quarter, compared to analyst estimates of $136.28 million. During the same quarter in the prior year, the firm earned $0.23 earnings per share. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. On average, analysts expect Penumbra to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.27 and a current ratio of 5.15. The company has a 50-day moving average price of $187.93 and a two-hundred day moving average price of $175.68. Penumbra has a 12 month low of $121.80 and a 12 month high of $225.64. The firm has a market cap of $7.88 billion, a PE ratio of 303.42 and a beta of 0.64.
In other news, EVP Lynn Rothman sold 200 shares of the stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $195.00, for a total value of $39,000.00. Following the completion of the sale, the executive vice president now directly owns 12,532 shares in the company, valued at $2,443,740. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Arani Bose sold 10,000 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $185.07, for a total transaction of $1,850,700.00. Following the completion of the sale, the insider now owns 560,662 shares of the company’s stock, valued at $103,761,716.34. The disclosure for this sale can be found here. Insiders have sold 44,151 shares of company stock valued at $8,226,190 over the last 90 days. 8.90% of the stock is currently owned by company insiders.
Penumbra Company Profile
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Featured Article: Do Tariffs Work?
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.